Ignite Creation Date:
2024-05-06 @ 7:26 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06014580
Status:
RECRUITING
Last Update Posted:
2024-02-20
First Post:
2023-06-15
Brief Title:
Molecular and Epidemiological Characteristics of Endometrial Cancer in Brazil
Sponsor:
Latin American Cooperative Oncology Group
Organization:
Latin American Cooperative Oncology Group
Study Overview
Official Title:
Molecular and Epidemiological Characteristics of Endometrial Cancer in Brazil
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MADONNA
Brief Summary:
An evaluation of the molecular and epidemiological aspects of endometrial cancer in Brazil is necessary to understand the high frequency of advanced disease A better understanding of the current situation will generate essential data for the future development of national or international cooperative programs that aim to improve outcomes in these patients and generate additional knowledge for much-needed clinical trials in this population
Detailed Description:
This is a retrospective observational cohort study In this study we will include patients diagnosed with endometrium cancer from January 2016 to December 2019 in participating sites and collect data on demographics clinicopathological characteristics treatment patterns and outcomes Data will be collected from medical records in selected centers that comprise different regions of Brazil
The patient data sources will be the medical records of the patients Patients will continue to receive treatment and clinical evaluations for endometrial cancer according to what is determined by their medical team according to the usual standards of treatment and clinical practice of each center To minimize patient selection bias physicians should invite all consecutive eligible patients
This study also provides for the collection and archiving of tumor tissue material The samples will be tested to characterize the molecular subtype of endometrial cancer and will be sequentially stored in a biorepository to enable future translational studies according to national regulations
The patient data sources will be the medical records of the patients Patients will continue to receive treatment and clinical evaluations for endometrial cancer according to what is determined by their medical team according to the usual standards of treatment and clinical practice of each center To minimize patient selection bias physicians should invite all consecutive eligible patients
This study also provides for the collection and archiving of tumor tissue material The samples will be tested to characterize the molecular subtype of endometrial cancer and will be sequentially stored in a biorepository to enable future translational studies according to national regulations
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None